MX2009003658A - Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. - Google Patents
Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.Info
- Publication number
- MX2009003658A MX2009003658A MX2009003658A MX2009003658A MX2009003658A MX 2009003658 A MX2009003658 A MX 2009003658A MX 2009003658 A MX2009003658 A MX 2009003658A MX 2009003658 A MX2009003658 A MX 2009003658A MX 2009003658 A MX2009003658 A MX 2009003658A
- Authority
- MX
- Mexico
- Prior art keywords
- coa desaturase
- containing heterocyclic
- heterocyclic compounds
- bicyclic nitrogen
- stearoyl
- Prior art date
Links
- 108010087894 Fatty acid desaturases Proteins 0.000 title abstract 4
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 title abstract 4
- -1 Bicyclic nitrogen-containing heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010039792 Seborrhoea Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000037312 oily skin Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84964806P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/080627 WO2008043087A2 (en) | 2006-10-05 | 2007-10-05 | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003658A true MX2009003658A (es) | 2009-04-22 |
Family
ID=39106151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003658A MX2009003658A (es) | 2006-10-05 | 2007-10-05 | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7732453B2 (enExample) |
| EP (1) | EP2066665A2 (enExample) |
| JP (1) | JP2010505881A (enExample) |
| KR (1) | KR20090057416A (enExample) |
| CN (1) | CN101522676A (enExample) |
| AU (1) | AU2007303056A1 (enExample) |
| BR (1) | BRPI0717502A2 (enExample) |
| CA (1) | CA2665476A1 (enExample) |
| IL (1) | IL197828A0 (enExample) |
| MX (1) | MX2009003658A (enExample) |
| RU (1) | RU2009112397A (enExample) |
| WO (1) | WO2008043087A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505881A (ja) * | 2006-10-05 | 2010-02-25 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルCoAデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物 |
| US7893066B2 (en) * | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
| EP2131844A1 (en) * | 2007-04-09 | 2009-12-16 | CV Therapeutics Inc. | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20090105283A1 (en) * | 2007-04-11 | 2009-04-23 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| PT2247292T (pt) * | 2008-03-05 | 2017-07-17 | Merck Patent Gmbh | Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes |
| KR20100132999A (ko) * | 2008-04-04 | 2010-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 스테아로일 CoA 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체 |
| EP2274308A1 (en) * | 2008-04-04 | 2011-01-19 | Gilead Sciences, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| WO2009126123A1 (en) * | 2008-04-10 | 2009-10-15 | Cv Therapeutics Inc. | Bicyclic nitrogen containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | 癌を治療するためのscd1アンタゴニスト |
| RU2606230C1 (ru) * | 2015-10-20 | 2017-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | (Z)-Этил 2-(4-(4-хлорфенил)-2,4-диоксо-3-(3-оксо-3,4-дигидрохиноксалин-2(1Н)-илиден)бутанамидо)-4-метил-5-фенилтиофен-3-карбоксилат, обладающий противодиабетической активностью, и способ его получения |
| AU2017236879B2 (en) * | 2016-03-22 | 2022-07-21 | Balchem Corporation | Compositions comprising choline |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| EP3914593A4 (en) | 2019-01-24 | 2022-11-02 | Yumanity Therapeutics, Inc. | CONNECTIONS AND USES THEREOF |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN118161500A (zh) | 2019-11-25 | 2024-06-11 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ,エルエルシー | Gcn2およびperkキナーゼ阻害剤およびその使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA2020073A1 (en) | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
| KR20010042298A (ko) * | 1998-03-31 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인자 Xa 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논 |
| KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| CA2393896A1 (en) | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| WO2002076954A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003076416A1 (en) | 2002-03-08 | 2003-09-18 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| US20040142950A1 (en) | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| CN1829701A (zh) * | 2003-07-30 | 2006-09-06 | 泽农医药公司 | 哌嗪衍生物和它们作为治疗剂的用途 |
| EP1830869B1 (en) | 2004-12-24 | 2013-05-22 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
| JP2010505881A (ja) * | 2006-10-05 | 2010-02-25 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルCoAデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物 |
| US7893066B2 (en) | 2006-10-05 | 2011-02-22 | Gilead Palo Alto, Inc. | Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors |
| EP2131844A1 (en) | 2007-04-09 | 2009-12-16 | CV Therapeutics Inc. | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20090105283A1 (en) | 2007-04-11 | 2009-04-23 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20080255161A1 (en) | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| EP2274308A1 (en) | 2008-04-04 | 2011-01-19 | Gilead Sciences, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| KR20100132999A (ko) | 2008-04-04 | 2010-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 스테아로일 CoA 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체 |
-
2007
- 2007-10-05 JP JP2009531633A patent/JP2010505881A/ja active Pending
- 2007-10-05 MX MX2009003658A patent/MX2009003658A/es not_active Application Discontinuation
- 2007-10-05 CA CA002665476A patent/CA2665476A1/en not_active Abandoned
- 2007-10-05 WO PCT/US2007/080627 patent/WO2008043087A2/en not_active Ceased
- 2007-10-05 RU RU2009112397/04A patent/RU2009112397A/ru not_active Application Discontinuation
- 2007-10-05 BR BRPI0717502-7A patent/BRPI0717502A2/pt not_active IP Right Cessation
- 2007-10-05 US US11/868,386 patent/US7732453B2/en not_active Expired - Fee Related
- 2007-10-05 KR KR1020097006958A patent/KR20090057416A/ko not_active Withdrawn
- 2007-10-05 AU AU2007303056A patent/AU2007303056A1/en not_active Abandoned
- 2007-10-05 CN CNA2007800367748A patent/CN101522676A/zh active Pending
- 2007-10-05 EP EP07853820A patent/EP2066665A2/en not_active Ceased
-
2009
- 2009-03-26 IL IL197828A patent/IL197828A0/en unknown
-
2010
- 2010-04-26 US US12/767,515 patent/US8148376B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007303056A1 (en) | 2008-04-10 |
| WO2008043087A2 (en) | 2008-04-10 |
| JP2010505881A (ja) | 2010-02-25 |
| CA2665476A1 (en) | 2008-04-10 |
| US8148376B2 (en) | 2012-04-03 |
| RU2009112397A (ru) | 2010-10-10 |
| KR20090057416A (ko) | 2009-06-05 |
| EP2066665A2 (en) | 2009-06-10 |
| BRPI0717502A2 (pt) | 2015-06-16 |
| WO2008043087A3 (en) | 2008-05-22 |
| IL197828A0 (en) | 2009-12-24 |
| US20080139570A1 (en) | 2008-06-12 |
| US20100204238A1 (en) | 2010-08-12 |
| US7732453B2 (en) | 2010-06-08 |
| CN101522676A (zh) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003658A (es) | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. | |
| MX2009010894A (es) | Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa. | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
| MX2008012490A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| MY153263A (en) | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | |
| MX2009005935A (es) | Compuestos biciclicos y su uso como anti-diabeticos. | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| MX2009012920A (es) | Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico. | |
| MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
| MX342423B (es) | Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio. | |
| ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
| MY149957A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| MX342128B (es) | Compuestos farmaceuticos. | |
| WO2007084314A3 (en) | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | |
| MX2012002633A (es) | Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes. | |
| WO2007137066A3 (en) | HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | |
| EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
| WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| EP1924293A4 (en) | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I | |
| CO6341563A2 (es) | Compuestos organicos | |
| MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
| MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
| IL213425A0 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |